Answers are grounded in this paper and cite their sources.
Glucagon-like peptide-1 (GLP-1) agonists have revolutionized the treatment of type 2 diabetes (T2DM) and obesity.1 These agents work by activating GLP-1 receptors in the pancreas, leading to increased insulin release and decreased glucagon release.2 Additionally, these agents can affect the GLP-1 receptors in the central nervous system and gastrointestinal tract, leading to decreased appetite and delayed glucose absorption due to slower gastric emptying.2 The first, Exenatide, was approved in 2005. Since then, GLP-1 receptor agonists, such as the semaglutide Ozempic (Novo Nordisk, Bagsværd, Denmark), have been widely used and are currently approved by the FDA for the treatment of T2DM.1 In a landmark development in 2021, the FDA granted a new indication for the semaglutide Wegovy (Novo Nordisk): chronic weight management in people 12 years of age and older.1 By 2022, tirzepatide (Mounjaro; Eli Lilly and Company, Indianapolis, IN) was approved for T2DM treatment by the FDA. This dual-action GLP-1 agonist/glucose-dependent insulinotropic peptide showed even more significant weight loss in clinical trials.1 As a result, in November 2023, under the brand name Zepbound (Eli Lilly and Company), tirzepatide's indications expanded to the treatment of obesity. GLP-1 agonists have captured widespread attention among the general public, particularly for their dramatic effects on weight loss. Off-label use for cosmetic weight reduction has surged with celebrity endorsements and extensive media coverage highlighting their dramatic results.1 Google searches for “Ozempic” have also spiked dramatically over the past 5 years, reflecting a growing fascination with nonsurgical weight loss.1 Unfortunately, the skyrocketing demand for GLP-1 agonists, both on- and off-label, has outpaced the supply of brand-name medications. Patients who rely on these agents for diabetes management are facing barriers to access, and pharmaceutical companies are struggling with frequent back-orders and shortages. Patients are fighting for insurance coverage, despite meeting FDA BMI criteria. Additionally, inefficient, cumbersome, and confusing prior authorization processes are creating further barriers to accessing these medications even when insurance offers complete or partial coverage. High costs are additional concerns, with Saxenda exceeding over $1300, Ozempic over $920, Wegovy over $1400, and Zepbound costing around $1060 for a 1-month supply.3,4 With no generic alternatives available, patients are being driven to seek GLP-1 agonists from unconventional sources, including compounding pharmacies, medical spas, and online websites.5 Due to the multitude of factors, medical providers, including obesity specialists, have turned to compounding pharmacies to provide these agents to their patients when no other options are available. Compounding pharmacies offer alternatives to brand-name drugs by mixing, combining, or altering FDA-approved drugs with varying ingredients to create a customized medication. Medications are often compounded for patients who are allergic to dyes in brand-name medications.4 Chemotherapy drugs are also often sourced from compounding pharmacies. These pharmacies must obtain the active pharmaceutical ingredients from FDA-registered facilities in order to adhere to Current Good Manufacturing Practices.4 In cases of drug shortages, compounding pharmacies in the United States can legally produce “a copy” of the medication.4 In May 2023, the FDA listed Ozempic and Wegovy as drugs in shortage, permitting compounded versions.4 This provision allows compounding pharmacies to address gaps in supply, offering patients more immediate access to these sought-after treatments. However, legislation regarding compounded medications varies by state. Despite their utility, compounded GLP-1 agonists pose significant safety concerns. Unlike FDA-regulated pharmaceuticals, compounded medications do not undergo the same rigorous scrutiny. For instance, despite being on the FDA drug shortage list, both Novo Nordisk and Eli Lilly have not provided the active ingredients to compounding pharmacies, raising questions about the purity and efficacy of the compounds being used.5,6 Some pharmacies may use semaglutide in its sodium salt form, which the FDA has not approved for human use due to the lack of safety and efficacy data.5 Moreover, reports have surfaced about some compounding pharmacies engaging in dubious practices, such as selling formulations labeled “not for human use” or without requiring prescriptions.5 Not only is the compounded medication chemically different from the FDA-approved GLP-1 agonist, but the FDA has also received reports of troubling practices, including using toaster ovens for sterilization and placing pet beds near sterile compounding areas.7 One compounding pharmacy, ACA Pharmacy, overwhelmed with compounded semaglutide prescriptions, hired technicians without pharmaceutical training and failed to maintain sterile conditions.8 Eventually, during discussions about its immediate suspension by the Tennessee Board of Pharmacy, ACA preemptively closed.8 This is not the first time compounding pharmacies have been found to demonstrate comprised safety standards. In 2012, fungal contamination from preparing formulations in a nonsterile environment at the former New England Compound Center caused a meningitis outbreak.5 In addition to environmental safety concerns, there also has been concern over proper dispensing and dosing of medications from compounding pharmacies. One case series reported up to 10-fold dosing inaccuracies in compounded semaglutide, resulting in gastrointestinal symptoms, including abdominal pain, nausea, and vomiting, lasting for days.9 The medications from compounding pharmacies are often dispensed as vials requiring patients to draw the correct amount of medication themselves, thus removing the safety features provided by prefilled manufactured pens.9 Additionally, some compounding pharmacies use syringes not intended for GLP-1 agonists (eg, insulin syringes) that can contribute to the variability of dosing units, resulting in patient confusion especially when transferring a prescription from one pharmacy to another.9 Due to these safety concerns, the FDA has released a statement advising patients not to use compounded medications if an FDA-approved form of that medication is available.5 Warnings from Novo Nordisk10 and Eli Lilly6 about the use of compounded GLP-1 agonists have further heightened this general apprehension. With the history of some antiobesity medications being on the market and then subsequently being withdrawn due to safety issues,11 there is a stigma within the healthcare community about prescribing these medications and concern about their general safety, potentially fueling further mistrust towards compounding GLP-1 agonists. It cannot be underscored enough that GLP-1 agonists have contraindications and side effects that should be discussed with any patient considering this medication and monitored closely by a trained medical professional at regular intervals. Despite these safety concerns over compounded GLP-1 agonists, access to these medications remains challenging, and demand continues to increase across indications. High costs and difficulties in obtaining prescriptions persist even with compounded options. Frustrated patients search for these medications internationally, from countries such as Mexico and Canada, or through online vendors, which poses additional risks.3 Currently, there are several legal proceedings underway regarding weight-loss clinics, medical spas, wellness clinics, and compounding pharmacies producing and selling these medications.3 FDA-approved brand-name formulations (ie, Wegovy, Zepbound) should always be offered as first-line when either covered by a patient's insurance or if a patient is willing to pay out-of-pocket. If brand-name formulations are not a feasible choice, compounded medications as a second-line option should be considered. Although safety concerns over compounded GLP-1 agonists are valid, legal and certified versions of these medications can still be obtained from more reputable and regulated compounding pharmacies. These pharmacies must operate under federal and state regulations and dispense medications only with a prescription from a licensed physician.4 Compounding pharmacies in the United States fall into 2 categories: 503A and 503B.4 FDA-designated 503A compounding pharmacies are required to use state-licensed pharmacists and physicians, who must prescribe medications that comply with United States Pharmacopeia standards, and must meet other state-specific regulations.4 These pharmacies are limited to dispensing only for home use and are restricted from producing large batches of compounds. In contrast, 503B pharmacies operate on a larger scale and are federally regulated by the FDA.4 When using compounding pharmacies to prescribe GLP-1 agonists to patients, providers should be aware of the following details to ensure that their pharmacy of choice is reputable, ethical, and safe (Figure 1). First, providers should only prescribe from pharmacies accredited by the Pharmacy Compounding Accreditation Board to ensure compliance with regulatory standards. Next, providers should receive clear and pharmacy-specific prescription instructions from the pharmacy and pharmacist to ensure that the prescription explicitly states that the compounded GLP-1 agonist is the base compound without any additives, such as salts. Providers should also request a Certificate of Analysis from the pharmacy to verify the quality and composition of the compounded medication. In addition, providers should verify the sterility of the pharmacy and inquire about production conditions, production locations (ie, ascertain US production) and third-party testing to ensure the highest safety standards are met. It is also important to clarify dosing instructions as each pharmacy is different, particularly if the prescription is transferred between pharmacies, causing confusion for patients and increased risk for incorrect dosing. Prescribers should continue to maintain regular follow-ups, typically every 1 to 3 months, to monitor the patient's response and any adverse effects, adjusting treatment as necessary. Lastly, providers should obtain and document informed consent from the patient before prescribing a compounded medication, making sure to emphasize the possible issues as described earlier in this article. By adhering to these guidelines, providers can navigate the complexities of prescribing GLP-1 agonists in a way that prioritizes patient well-being, particularly in the current environment in which conventional FDA-approved GLP-1 agonist options are limited. Checklist for prescribing GLP-1 agonists from compounding pharmacies. GLP-1, glucagon-like peptide-1. Adding to the confusion of compounded products are FDA-approved, private-label manufacturers (eg, Nomida). These companies receive National Drug Code directory numbers and approval but are not subject to the same regulations as a pharmacy. For example, this allows shipping to all 50 states, even to those that currently ban compounded drugs, while ensuring FDA oversight. As GLP-1 agonists have proven to be powerful in regulating blood sugar and driving weight loss, new indications for this medication have recently been explored (Figure 2). Most recently, Wegovy (semaglutide) was approved to reduce the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in adults with established cardiovascular disease.12 In addition, a recent meta-analysis found that in patients living with obesity or overweight, GLP-1 agonists reduced systolic and diastolic blood pressure and the occurrence of myocardial infarction.12 The future of GLP-1 agonists. GLP-1, glucagon-like peptide-1; NAFLD, nonalcoholic fatty liver disease; PCOS, polycystic ovarian syndrome. Emerging evidence suggests that GLP-1 agonists can help reduce cravings in alcohol use disorder and potentially other compulsive behaviors, including food and shopping addictions.13 Interestingly, substantial preclinical evidence in rodents and nonhuman primates has shown the GLP-1 agonists can influence compulsive and reward-related behaviors due to their dopamine-releasing action in the nucleus accumbens.14,15 Indeed, in an as yet unpublished study, our group found that addictive behaviors across the board are significantly reduced in patients taking GLP-1 agonists up to 6 months after cessation of the drug. In addition, patients with polycystic ovarian syndrome have reported more regular menstrual cycles and improved fertility with GLP-1 agonists, providing an additional therapeutic option beyond conventional treatments such as diet changes, birth control pills, and metformin.16 GLP-1 agonists have also been reported to reduce aminotransferase levels and improve liver histology in patients with nonalcoholic fatty liver disease by improving insulin resistance and lowering inflammation.17 This growing evidence suggests that GLP-1 agonists could serve as a superior treatment option for patients with nonalcoholic fatty liver disease.17 Currently, research is ongoing into the use of GLP-1 agonists for conditions such as obstructive sleep apnea and kidney disease, indicating a broad and growing therapeutic scope.18,19 Given their demonstrated safety, efficacy, and expanding range of applications, GLP-1 agonists are set to remain a key component of obesity management and potentially other diseases. However, their rising popularity and the potential for misuse underscore the need for vigilant monitoring and the establishment of standardized safe-practice protocols. As leaders of the aesthetic world, it behooves the plastic surgery community to be at the forefront of creating such best-practice guidelines. As part of this endeavor, The Aesthetic Society might consider creating a comprehensive database to track individual experiences with GLP-1 agonists in order to stay ahead of emerging trends and ensure that GLP-1 agonists continue to be a safe and effective tool. This proactive approach will not only enhance patient safety but will also help to integrate these valuable medications into the broader spectrum of obesity care effectively and sustainably. To further reinforce and develop these guidelines, professional training, such as workshops, seminars, and webinars, should be implemented to educate healthcare professionals about prescribing GLP-1 agonists, in particular about the benefits and risks of these new drugs. The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article. The authors received no financial support for the research, authorship, and publication of this article.
No takes yet. Share an insight, caveat, or question.
Ockerman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: